Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2015;5(4):731-6.
doi: 10.3233/JPD-150666.

Peripheral Biomarkers of Parkinson's Disease Progression and Pioglitazone Effects

David K Simon  1 , Tanya Simuni  2 , Jordan Elm  3 , Joanne Clark-Matott  1 , Allison K Graebner  1 , Liana Baker  4 , Susan R Dunlop  5 , Marina Emborg  6 , Cornelia Kamp  7 , John C Morgan  8 , G Webster Ross  9 , Saloni Sharma  4 , Bernard Ravina  10 ; NINDS NET-PD Investigators
Affiliations
Clinical Trial

Peripheral Biomarkers of Parkinson's Disease Progression and Pioglitazone Effects

David K Simon et al. J Parkinsons Dis. 2015.

Abstract

Pioglitazone, an oral hypoglycemic agent, recently failed to show promise as a disease-modifying agent in a 44-week phase 2 placebo-controlled study in 210 Parkinson's disease (PD) subjects. We analyzed peripheral biomarkers, including leukocyte PGC-1α and target gene expression, plasma interleukin 6 (IL-6) as a marker of inflammation, and urine 8-hydroxydeoxyguanosine (8OHdG) as a marker of oxidative DNA damage. Baseline or changes from baseline in biomarker levels were not associated with the rate of progression of PD. Pioglitazone did not significantly alter biomarker levels. Other agents that more effectively target these mechanisms remain of potential interest as disease modifying therapies in PD.

Keywords: 8-hydroxydeoxyguano sine; 8OHdG; IL-6; PGC-1alpha; Parkinson’s disease; biomarker; cytokine; inflammation; interleukin-6; oxidative stress; pioglitazone.

PubMed Disclaimer

Conflict of interest statement

The authors have no conflicts of interest to report.

References

    1. Beal MF. Mitochondria, oxidative damage, and inflammation in Parkinson’s disease. Ann N Y Acad Sci. 2003;991:120–131. - PubMed
    1. Zheng B, Liao Z, Locascio JJ, Lesniak KA, Roderick SS, Watt ML, Eklund AC, Zhang-James Y, Kim PD, Hauser MA, Grunblatt E, Moran LB, Mandel SA, Riederer P, Miller RM, Federoff HJ, Wullner U, Papapetropoulos S, Youdim MB, Cantuti-Castelvetri I, Young AB, Vance JM, Davis RL, Hedreen JC, Adler CH, Beach TG, Graeber MB, Middleton FA, Rochet JC, Scherzer CR. PGC-1alpha, a potential therapeutic target for early intervention in Parkinson’s disease. Sci Transl Med. 2010;2:52ra73. - PMC - PubMed
    1. Shin JH, Ko HS, Kang H, Lee Y, Lee YI, Pletinkova O, Troconso JC, Dawson VL, Dawson TM. PARIS (ZNF746) repression of PGC-1alpha contributes to neurodegeneration in Parkinson’s disease. Cell. 2011;144:689–702. - PMC - PubMed
    1. Siddiqui A, Chinta SJ, Mallajosyula JK, Rajagopolan S, Hanson I, Rane A, Melov S, Andersen JK. Selective binding of nuclear alpha-synuclein to the PGC1alpha promoter under conditions of oxidative stress may contribute to losses in mitochondrial function: Implications for Parkinson’s disease. Free Radic Biol Med. 2012;53:993–1003. - PMC - PubMed
    1. Clark J, Simon DK. Transcribe to Survive: Transcriptional control of antioxidant defense programs for neuroprotection in Parkinson’s disease. Antioxid Redox Signal. 2009;11:509–528. - PubMed

Publication types

MeSH terms